tirzepatide works better than semaglutide Comparing and for Weight Loss: A Rochester M.D.'s View Tirzepatide vs Semaglutide: 2025 NEJM

Active ingredient: Liraglutide, Semaglutide

Major trials conducted in patients with MASLD have reported prevalence rates of 4246%, 1938%, and 1519% for these symptoms, respectively

As of May 2026, the FDA has received 990 reports of adverse events associated specifically with compounded versions of this medication

Published Phase 2 trial data (NEJM, 2023) demonstrated substantial reductions in body weight in some participants exceeding 20% over approximately 48 weeks making retatrutide one of the most potent agents currently in development for obesity and metabolic disease

It is solely at the doctor's professional discretion